Nav: Home

Study points to new strategy for boosting immunotherapy effectiveness in advanced colorectal cancer

March 21, 2019

Researchers at The University of Texas MD Anderson Cancer Center revealed the common oncogene KRAS as a possible explanation for why many patients with metastatic colorectal cancer (CRC) do not respond to immune checkpoint blockade (ICB) therapy.

Findings from the study, published in the March 21 online issue of Cancer Cell, shows how KRAS, a key mutation in colorectal cancer, promotes metastasis by controlling the immune-suppressive capabilities of the tumor microenvironment. The study results reveals how KRAS and its downstream target genes interact, supporting further study of a new approach to enhancing ICB therapy.

CRC is a major cause of cancer mortality worldwide. Approximately 20 percent of patients have metastatic disease at the time of diagnosis, and, despite improvements in treatments, approximately 12 percent of patients survive to five years. The quest for new effective treatments or improvements to standard-of-care therapies is crucial.

"The majority of colorectal cancer patients do not respond to immune checkpoint blockade therapy, motivating the need for study of mechanisms and combination regimens with targeted therapies and ICB," said Ronald A. DePinho, M.D., professor of Cancer Biology. "Our study established an essential role for KRAS in modulating immune microenvironment and primary ICB resistance in advanced CRC."

Using a genetically engineered mouse model, DePinho's team demonstrated how a KRAS-regulated gene called interferon regulatory factor 2 (IRF2) drives immune suppression and immune therapy resistance in CRC. They showed that KRAS dampened IRF2 expression, which in turn, resulted in high expression of a protein-encoding gene called C-X-C motif chemokine ligand 3 (CXCL3). CXCL3 binds to its receptor, CXCR2, which is found on myeloid-derived suppressor cells (MDSC) that promote immune suppression and metastasis. The researchers found that restoration of IRF2 expression, or therapeutic inhibition of MDSC by targeting CXCL3-CXCR2 signaling, increased CRC sensitivity to ICB therapy.

"This KRAS-IRF2-CXCL2-CXCR3 axis provides a framework for determining which patients may respond better to ICB, and potentially identifying combination therapy to enhance ICB therapy effectiveness," said DePinho. "It remains possible that KRAS mutation status in metastatic CRC could be a predictor of ICB resistance when mediated by IRF2 suppression. Our studies suggest the use of combination CXCR2 inhibitor with ICB therapy in patients with advanced CRC who do not respond to today's standard of care immunotherapy."
-end-
MD Anderson study team participants included Wenting Liao, Ph.D.; Adam Boutin, Ph.D.; Xiaoying Shang, Ph.D.; Di Zhao, Ph.D.; Prasenjit Dey,, Ph.D.; Jiexi Li; Guocan Wang, M.D., Ph.D.; Zhengdao Lan; Shan Jian, Ph.D.; Xingdi Ma; Peiwen Chen, Ph.D.; Deepavali Chakravarti, Ph.D.; Andrew Chang; Denise Spring, Ph.D.; and Y. Alan Wang, Ph.D., all of the Department of Cancer Biology; Jun Li, Ph.D.; Ming Tang, M.D., Ph.D.; and Jianhua Zhang, Ph.D., of the Department of Genomic Medicine; Riham Katkhuda, M.D.; and Dipen Maru, M.D., of the Department of Pathology; Michael Overman, M.D.; Krittiya Korphaisarn, M.D.; and Scott Kopetz M.D., Ph.D., of the Department of Gastrointestinal Medical Oncology; and Qing Chang, M.D., of the Institute for Applied Cancer Science.

Other participating institutions included Southern Medical University, Guangzhou, China; and Syntrix Pharmaceuticals, Auburn, Wash.

A full disclosure of conflicts of interest can be found with the full study.

The study was funded by the National Institutes of Health (CA084628 and 01 CA117969); the National Basic Research Program of China (2015CB554002); the National Natural Science Foundation of China (81672886, 81773101, and 81872401); and the Cancer Prevention and Research Institute of Texas (RP170067). The study was also supported with funding from the Colorectal Cancer Moon Shot™, part of MD Anderson's Moon Shots Program™, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients' lives.

University of Texas M. D. Anderson Cancer Center

Related Colorectal Cancer Articles:

Colorectal cancer rates in Canada
The incidence of colorectal cancer among younger adults increased in recent years in this analysis of data from Canadian national cancer registries that included about 688,000 new colorectal cancers diagnosed over more than 40 years.
Cancer drugs promote stem cell properties of colorectal cancer
Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors) activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells.
Aspirin before at-home colorectal cancer screening test didn't significantly improve ability to detect cancer precursors
Some observational studies have suggested that taking aspirin before undergoing colorectal cancer screening with a fecal immunochemical test for blood in stool might improve the ability of the test to detect cancer precursors.
Gene involved in colorectal cancer also causes breast cancer
Rare mutations in the NTHL1 gene, previously associated with colorectal cancer, also cause breast cancer and other types of cancer.
Bug that causes stomach cancer could play a role in colorectal cancer
A bacterium known for causing stomach cancer might also increase the risk of certain colorectal cancers, particularly among African Americans, according to a study led by Duke Cancer Institute researchers.
'Chromosomal catastrophes' in colorectal cancer
'Chromosomal catastrophes' have been found to occur along the evolutionary timeline of colorectal cancer development, according to new research led by Queen Mary University of London.
Colorectal cancer: Tipping the scales
Tumors of the colon are among the most prevalent cancers.
American Cancer Society updates colorectal cancer screening guideline
An updated American Cancer Society guideline says colorectal cancer screening should begin at age 45 for people at average risk, based in part on data showing rates are increasing in young and middle-aged populations.
New 'Scoring' System for Advanced Colorectal Cancer
Georgios Margonis, M.D., Ph.D., a surgical oncology fellow at the Johns Hopkins University School of Medicine, and Matthew Weiss, M.D., surgical director of the Johns Hopkins Liver and Pancreas Cancer Multidisciplinary Clinics, report advances in efforts to improve the treatment and prognosis of colorectal cancers that have spread to the liver.
How colorectal cancer cells spread to the liver
A new study by Sanford Burnham Prebys Medical Discovery Institute (SBP) researchers helps explain the connection between a tumor suppressor called protein kinase C zeta (PKC zeta) and metastatic colorectal cancer.
More Colorectal Cancer News and Colorectal Cancer Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

In & Out Of Love
We think of love as a mysterious, unknowable force. Something that happens to us. But what if we could control it? This hour, TED speakers on whether we can decide to fall in — and out of — love. Guests include writer Mandy Len Catron, biological anthropologist Helen Fisher, musician Dessa, One Love CEO Katie Hood, and psychologist Guy Winch.
Now Playing: Science for the People

#541 Wayfinding
These days when we want to know where we are or how to get where we want to go, most of us will pull out a smart phone with a built-in GPS and map app. Some of us old timers might still use an old school paper map from time to time. But we didn't always used to lean so heavily on maps and technology, and in some remote places of the world some people still navigate and wayfind their way without the aid of these tools... and in some cases do better without them. This week, host Rachelle Saunders...
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at Radiolab.org/donate.